Discussion
The 150 mg dose of solengepras (CVN424), Cerevance’s investigational oral treatment for Parkinson’s disease, significantly reduced average daily off time — periods when symptoms reappear despite medication — compared with placebo, according to topline results from a Phase 3 trial. The Phase 3 ARISE trial (NCT06553027) evaluated…
